18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours

Nanni, Cristina; Rubello, Domenico; Castellucci, Paolo; Farsad, Mohsen; Franchi, Roberta; Rampin, Lucia; Gross, Milton D.; Al-Nahhas, Adil; Fanti, Stefano

doi:10.1016/j.biopha.2006.07.091

Cited by 33 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 F-FDG-6-phosphate entrapped, and steadily accumulates in metabolically active cells with different uptake mechanism with 123 I-MIBG21). Although most NBL and associated metastases have been shown to have good avidity for FDG, 18 F-FDG PET have shown variable results during/after treatment due to its lower tumor-to-nontumor uptake ratio and FDG uptake in nontumor sites4,22). 18 F-FDG PET also show false positive results in osteo-medullary assessment due to diffuse BM uptake after treatment (hyperactivity) with growth factors or radio-chemotherapy (rebound after treatment).…”

Section: Discussionmentioning

confidence: 99%

Clinical experience with¹⁸F-fluorodeoxyglucose positron emission tomography and¹²³I-metaiodobenzylguanine scintigraphy in pediatric neuroblastoma: complementary roles in follow-up of patients

Gil

Lee

et al. 2014

Korean J Pediatr

View full text Add to dashboard Cite

PurposeTo evaluate the potential utility of 123I-metaiodobenzylguanine (123I-MIBG) scintigraphy and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) for the detection of primary and metastatic lesions in pediatric neuroblastoma (NBL) patients, and to determine whether 18F-FDG PET is as beneficial as 123I-MIBG imaging.MethodsWe selected 8 NBL patients with significant residual mass after operation and who had paired 123I-MIBG and 18F-FDG PET images that were obtained during the follow-up. We retrospectively reviewed the clinical charts and the findings of 45 paired scans.ResultsBoth scans correlated relatively well with the disease status as determined by standard imaging modalities during follow-up; the overall concordance rates were 32/45 (71.1%) for primary tumor sites and 33/45 (73.3%) for bone-bone marrow (BM) metastatic sites. In detecting primary tumor sites, 123I-MIBG might be superior to 18F-FDG PET. The sensitivity of 123I-MIBG and 18F-FDG PET were 96.7% and 70.9%, respectively, and their specificity were 85.7% and 92.8%, respectively. 18F-FDG PET failed to detect 9 true NBL lesions in 45 follow-up scans (false negative rate, 29%) with positive 123I-MIBG. For bone-BM metastatic sites, the sensitivity of 123I-MIBG and 18F-FDG PET were 72.7% and 81.8%, respectively, and the specificity were 79.1% and 100%, respectively. 123I-MIBG scan showed higher false positivity (20.8%) than 18F-FDG PET (0%).Conclusion123I-MIBG is superior for delineating primary tumor sites, and 18F-FDG PET could aid in discriminating inconclusive findings on bony metastatic NBL. Both scans can be complementarily used to clearly determine discrepancies or inconclusive findings on primary or bone-BM metastatic NBL during follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical experience with¹⁸F-fluorodeoxyglucose positron emission tomography and¹²³I-metaiodobenzylguanine scintigraphy in pediatric neuroblastoma: complementary roles in follow-up of patients

Gil

Lee

et al. 2014

Korean J Pediatr

View full text Add to dashboard Cite

show abstract

“…There are extensive data in this area (TaBle 5) [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50].…”

Section: Pet/ct In Detecting Disease Recurrence Of Ovarian Carcinomamentioning

confidence: 99%

Impact of FDG-PET and -PET/CT Imaging in the Clinical Decision-Making of Ovarian Carcinoma: An Evidence-Based Approach

Dhingra¹,

Kand

Basu

2012

Womens Health (Lond Engl)

View full text Add to dashboard Cite

The most definitive role of fluorodeoxyglucose (FDG)-PET/computed tomography (CT) at present is surveillance and detecting recurrence in patients who have completed primary therapy but demonstrate a rising serum tumor marker (e.g., CA-125 levels). In this scenario, PET/CT demonstrates high sensitivity and accuracy in detecting lesions that are otherwise challenging, and appears superior (with less interobserver variability) compared with CT alone. Despite the fact that peritoneal deposits may be missed by PET/CT, the overall performance is better than CT alone. FDG-PET does not play a significant additional role in the primary diagnosis of ovarian cancers; however, the role of combined PET/CT modality has recently begun to be re-explored for initial disease staging, particularly because PET/CT can pick up small unsuspected lesions and thereby provide a better disease assessment of the whole body in a single examination. The baseline PET/CT also subserves an important role for future monitoring of therapy response. Therapy monitoring by PET could help to optimize neoadjuvant therapy protocols and to avoid ineffective therapy in nonresponders early in its course, although PET/CT has cost-effectiveness issues that need further evaluation. The prognostic value of FDG-PET/CT has been investigated in the following areas: in the preoperative setting to predict optimal cytoreduction; to assess the value of a positive FDG-PET following primary surgery; and when employed as a replacement for second-look laparotomy following completion of primary surgery and chemotherapy. The data, although promising, are still sparse in all the three domains for a definite recommendation.

show abstract

“…18 F-FDG PET/PET-CT has been shown to provide useful information in evaluating a wide variety of pediatric tumors [1–5]. In a modest cohort of pediatric oncology patients, Wegner et al [3] reported that PET-CT changed the management of malignant diseases in 24% of cases and was reported to be useful in disease assessment in 75%.…”

Section: Established Uses In Pediatric Oncologymentioning

confidence: 99%

“…PET-CT is proving to be useful in the evaluation of neuroblastoma [4, 5, 8, 15, 16] and Wilms tumor [2, 17–21]. At least in the case of Wilms tumor, preliminary experience suggests that the intensity of metabolic activity seems to correlate with the degree of histological differentiation [18, 19].…”

Section: Established Uses In Pediatric Oncologymentioning

confidence: 99%

PET-CT in children: where is it appropriate?

Kaste

2011

Pediatr Radiol

View full text Add to dashboard Cite

The use of PET/PET-CT is a rapidly growing area of imaging and research in the care of children. Until recently, diagnostic imaging methods have provided either anatomical or functional assessment. The development of fused imaging modalities, such as PET-CT or PET-MRI, now provides the opportunity for simultaneously providing both anatomical and functional or physiological assessment. This review will discuss current established uses of PET-CT, possible uses and potential research investigations in the use of this modality in the pediatric population. The focus of this paper will be its use in children being treated for non-central nervous system and non-cardiac disorders.

show abstract

18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours

Cited by 33 publications

References 29 publications

Clinical experience with¹⁸F-fluorodeoxyglucose positron emission tomography and¹²³I-metaiodobenzylguanine scintigraphy in pediatric neuroblastoma: complementary roles in follow-up of patients

Clinical experience with¹⁸F-fluorodeoxyglucose positron emission tomography and¹²³I-metaiodobenzylguanine scintigraphy in pediatric neuroblastoma: complementary roles in follow-up of patients

Impact of FDG-PET and -PET/CT Imaging in the Clinical Decision-Making of Ovarian Carcinoma: An Evidence-Based Approach

PET-CT in children: where is it appropriate?

Contact Info

Product

Resources

About

18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours

Cited by 33 publications

References 29 publications

Clinical experience with18F-fluorodeoxyglucose positron emission tomography and123I-metaiodobenzylguanine scintigraphy in pediatric neuroblastoma: complementary roles in follow-up of patients

Clinical experience with18F-fluorodeoxyglucose positron emission tomography and123I-metaiodobenzylguanine scintigraphy in pediatric neuroblastoma: complementary roles in follow-up of patients

Impact of FDG-PET and -PET/CT Imaging in the Clinical Decision-Making of Ovarian Carcinoma: An Evidence-Based Approach

PET-CT in children: where is it appropriate?

Contact Info

Product

Resources

About

Clinical experience with¹⁸F-fluorodeoxyglucose positron emission tomography and¹²³I-metaiodobenzylguanine scintigraphy in pediatric neuroblastoma: complementary roles in follow-up of patients

Clinical experience with¹⁸F-fluorodeoxyglucose positron emission tomography and¹²³I-metaiodobenzylguanine scintigraphy in pediatric neuroblastoma: complementary roles in follow-up of patients